MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
MediWound Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$12.70+0.85 (+7.17%)
Close on Oct 19, 2026
- Market cap
- $167.72M
- P/E (TTM)
- –
- Dividend yield
- –
MediWound Ltd. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $11.78M | $15.46M | $13.08M | – | – | – | – | – | – | 69.5% | -23.8% |
| Rest of the world [Member] | $2.07M | $2.28M | $2.60M | $4.62M | $5.66M | $3.73M | $3.29M | – | – | 12.2% | -9.4% |
| Spain | $1.29M | $840.00K | $1.04M | – | – | – | – | – | – | 7.6% | +53.7% |
| Italy | $1.00M | $817.00K | $1.02M | – | – | – | – | – | – | 5.9% | +22.6% |
| Germany | $817.00K | $824.00K | $949.00K | – | – | – | – | – | – | 4.8% | -0.8% |
| USA [Member] | – | $15.46M | $13.08M | $21.87M | $18.10M | $18.03M | $28.50M | – | – | – | – |
By product or service
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rest of the world [Member] | – | – | – | – | – | $3.73M | $3.29M | $3.40M | $2.50M | – | – |
| USA [Member] | – | – | – | – | – | $18.03M | $28.50M | – | – | – | – |
From the segment and revenue-disaggregation notes of MediWound's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.